HR 1262 · 119th Congress 2025–2027

Mikaela Naylon Give Kids a Chance Act

Latest action · Dec 2, 2025 Received in the Senate.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedFeb 12, 2025
  2. Passed HouseDec 1, 2025
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Give Kids a Chance Act of 2025

This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. 

Specifically, the bill

  • modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;
  • permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;
  • renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and
  • reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. 

The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Cosponsors 313

Members who signed on, in the order they did. Signatures ran from Feb 12, 2025 to Oct 31, 2025; 10 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-TXDan CrenshawOriginalFeb 12, 2025
D-MIDebbie DingellOriginalFeb 12, 2025
R-TNDiana HarshbargerOriginalFeb 12, 2025
D-CADoris O. MatsuiOriginalFeb 12, 2025
R-FLGus M. BilirakisOriginalFeb 12, 2025
D-FLKathy CastorOriginalFeb 12, 2025
D-WAKim SchrierOriginalFeb 12, 2025
D-MALori TrahanOriginalFeb 12, 2025
R-PAMike KellyOriginalFeb 12, 2025
R-TXRandy K. Weber, Sr.OriginalFeb 12, 2025
R-VABen ClineFeb 24, 2025
R-FLCarlos A. GimenezFeb 24, 2025
R-WVCarol D. MillerFeb 24, 2025
R-LAClay HigginsFeb 24, 2025
D-FLDarren SotoFeb 24, 2025

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Feb 12, 2025Markup Sep 17, 2025Reported Oct 31, 2025

Actions 12

Everything that happened, newest first.

  1. Dec 2, 2025Received in the Senate.
  2. Dec 1, 2025Considered under suspension of the rules. (consideration: CR H4929-4935)
  3. Dec 1, 2025Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
  4. Dec 1, 2025Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended.
  5. Dec 1, 2025DEBATE - The House proceeded with forty minutes of debate on H.R. 1262.
  6. Dec 1, 2025Motion to reconsider laid on the table Agreed to without objection.
  7. Oct 31, 2025Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
  8. Oct 31, 2025Placed on the Union Calendar, Calendar No. 304.
  9. Sep 17, 2025Committee Consideration and Mark-up Session Held
  10. Sep 17, 2025Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 47 - 0.
  11. Feb 12, 2025Introduced in House
  12. Feb 12, 2025Referred to the House Committee on Energy and Commerce.

In the Congressional Record 4

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S8820–S8822Bernard Sanders I-VT, Bill Cassidy R-LA, Margaret Wood Hassan D-NH, Markwayne Mullin R-OKDec 17, 2025
HouseDebate and remarks H4929–H4935Text printed H4929–H4932Debbie Dingell D-MI, Earl L. "Buddy" Carter R-GA, Frank Pallone, Jr. D-NJ, Gus M. Bilirakis R-FL, Jay Obernolte R-CA, Michael T. McCaul R-TXDec 1, 2025
ExtensionsDebate and remarks E898Lori Trahan D-MASep 26, 2025
HouseDebate and remarks H1341John Joyce R-PAMar 31, 2025

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Committee report

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8,

The sponsor’s statement, as printed in the Congressional Record, vol. 171, no. 29, February 12, 2025, page H678.

Related bills 10

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 532OPTN Fee Collection Authority ActRelated billFeb 12, 2025
S 891Bipartisan Health Care ActRelated billMar 6, 2025
S 932Give Kids a Chance Act of 2025Related billMar 11, 2025
HR 1768Lower Costs for Everyday Americans ActRelated billMar 3, 2025
HR 1794United States-Abraham Accords Cooperation and Security Act of 2025Related billMar 3, 2025

Titles 5

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Short Title(s) as Introduced
Give Kids a Chance Act of 2025
Short Title(s) as Reported to House
Give Kids a Chance Act of 2025
Short Title(s) as Passed House
Mikaela Naylon Give Kids a Chance Act
Official Title from EH (Engrossed in House) bill text
To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 3

Each version as it was printed, newest first.

  1. Dec 1, 2025Engrossed in House
  2. Oct 31, 2025Reported in House
  3. Feb 12, 2025Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.